Merck shows PD-1's promise in breast cancer with positive early results

Merck's ($MRK) pembrolizumab, sold as Keytruda, showed promising signs of efficacy in a particularly deadly brand of breast cancer, early data that could expand the use for a new class of treatments expected to take the market by storm. Merck's treatment, approved to treat melanoma, charted an overall response rate of 18.5% in a study on women with triple-negative breast cancer, an aggressive form of the disease with no approved targeted therapies. The results suggest a wider use for so-called checkpoint inhibitors, a class of treatments that help expose cancer cells to the immune system's natural defenses and have thus far demonstrated efficacy in skin, lung and other cancers. Bristol-Myers Squibb ($BMY), Roche ($RHHBY) and AstraZeneca ($AZN) are among the companies developing similar therapies. More

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.